Century Therapeutics to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March:
- TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA.
- Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL.
A live webcast of the presentations will be available on the Investors page of Century’s website at www.centurytx.com. Archived replays will be available for at least 30 days.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
For More Information:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SOL Strategies shares jump 20% as firm posts validator network growth
EUR/USD Price Forecast: Falls to near 1.1600 due to persistent bearish bias
Impact Biomedical (IBO) Stock Jumps Over 86% After Hours - Here's Why

GitLab's Fourth Quarter: Results Met Expectations, But Guidance Revision Was Unexpected
